Patritumab deruxtecan is a specifically engineered HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck .

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, ...

Based on these overall survival data, Merck previously withdrew its biologics license application seeking FDA approval of patritumab deruxtecan for use in this setting. Additional Efficacy Data ...

Safety profiles favored patritumab deruxtecan, with fewer grade 3 or higher side effects compared to chemotherapy, supporting its potential as a neoadjuvant option. SHOW MORE Patients with high-risk, ...

Merck, Daiichi Sankyo Say Biologics License Application Withdrawn For Patritumab Deruxtecan May 29, 2025 — 08:06 am EDT Written by RTTNews.com for RTTNews -> ...

Daiichi Sankyo and Merck (known as MSD outside of the United States and Canada) entered into a global collaboration in October 2023 to jointly develop and commercialize patritumab deruxtecan (HER3 ...

Merck MRK announced that the FDA has granted breakthrough therapy designation (BTD) ... MRK’s deal with Daiichi involves three ADCs, namely patritumab deruxtecan, ...